newsfilter
← Latest News
GlobeNewswire·

Calithera Biosciences Announces Decision to Discontinue KEAPSAKE Clinical Trial

--KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat --Company will focus on advancing newly acquired targeted oncology compounds sapanisertib and mivavotinib, as well as the ongoing trial of CB-2